Detection of prostate-specific antigen (PSA) as a screening strategy for prostate cancer is limited by the inability of the PSA test to differentiate between malignant cancer and benign hyperplasia.

Replication-competent (oncolytic) adenovirus (Ad) vectors have been developed as a promising new tool in the fight against cancer. 1 The principal idea behind this approach is that the vector ...